Enzon Pharmaceuticals Performance
| ENZNDelisted Stock | USD 0.20 0.01 5.26% |
The firm shows a Beta (market volatility) of 0.0017, which means not very significant fluctuations relative to the market. As returns on the market increase, Enzon Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Enzon Pharmaceuticals is expected to be smaller as well. Enzon Pharmaceuticals right now shows a risk of 0.0%. Please confirm Enzon Pharmaceuticals downside variance, as well as the relationship between the accumulation distribution and market facilitation index , to decide if Enzon Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Enzon Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Enzon Pharmaceuticals is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 48.1 M | |
| Free Cash Flow | -501 K |
Enzon |
Enzon Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 20.00 in Enzon Pharmaceuticals on October 22, 2024 and sell it today you would earn a total of 0.00 from holding Enzon Pharmaceuticals or generate 0.0% return on investment over 90 days. Enzon Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of otc stocks are less volatile than Enzon, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Enzon Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Enzon Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Enzon Pharmaceuticals, and traders can use it to determine the average amount a Enzon Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ENZN |
Based on monthly moving average Enzon Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Enzon Pharmaceuticals by adding Enzon Pharmaceuticals to a well-diversified portfolio.
Enzon Pharmaceuticals Fundamentals Growth
Enzon OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Enzon Pharmaceuticals, and Enzon Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Enzon OTC Stock performance.
| Return On Equity | -0.016 | ||||
| Return On Asset | -0.0138 | ||||
| Operating Margin | (36.28) % | ||||
| Current Valuation | 17.63 M | ||||
| Shares Outstanding | 74.21 M | ||||
| Price To Earning | 1.52 X | ||||
| Price To Book | 7.41 X | ||||
| Price To Sales | 669.36 X | ||||
| Revenue | 701 K | ||||
| EBITDA | (469 K) | ||||
| Cash And Equivalents | 46.79 M | ||||
| Cash Per Share | 0.63 X | ||||
| Debt To Equity | 1.46 % | ||||
| Book Value Per Share | 0.04 X | ||||
| Cash Flow From Operations | (501 K) | ||||
| Earnings Per Share | (0.04) X | ||||
| Total Asset | 47.75 M | ||||
| Retained Earnings | (75.61 M) | ||||
| Current Asset | 11.78 M | ||||
| Current Liabilities | 4.8 M | ||||
About Enzon Pharmaceuticals Performance
By examining Enzon Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Enzon Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Enzon Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company was founded in 1981 and is headquartered in Cranford, New Jersey. Enzon Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Enzon Pharmaceuticals performance evaluation
Checking the ongoing alerts about Enzon Pharmaceuticals for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Enzon Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Enzon Pharmaceuticals is not yet fully synchronised with the market data | |
| Enzon Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Enzon Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 701 K. Net Loss for the year was (469 K) with profit before overhead, payroll, taxes, and interest of 701 K. | |
| Enzon Pharmaceuticals currently holds about 46.79 M in cash with (501 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Enzon Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Enzon Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Enzon Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Enzon Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Enzon Pharmaceuticals' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Enzon Pharmaceuticals' otc stock. These opinions can provide insight into Enzon Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in nation. Note that the Enzon Pharmaceuticals information on this page should be used as a complementary analysis to other Enzon Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Enzon OTC Stock
If you are still planning to invest in Enzon Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Enzon Pharmaceuticals' history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |